Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Williams

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
Biorxiv : the Preprint Server for Biology|November 3, 2020
Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromesRajendra Karki, Bhesh Raj Sharma, Shraddha Tuladhar, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
Plos Pathogens|August 14, 2015
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionMartina Kovarova, Olivia D Council, Abhijit A Date, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 30, 2019
[<sup>18</sup>F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's diseaseSandra Sanabria Bohórquez, Jan Marik, Annie Ogasawara, et al.
Science (New York, N.Y.)|December 14, 2004
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisKoen Andries, Peter Verhasselt, Jerome Guillemont, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2020
Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosisLucia Macken, Stephen Bremner, Heather Gage, et al.
Oncotarget|March 31, 2016
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1Simon-Peter Williams, Annie Ogasawara, Jeff N Tinianow, et al.
British Journal of Clinical Pharmacology|November 13, 2021
A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitorJack A Brown, Joanne Bal, Monica Simeoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2022
Preclinical development of ZED8, an <sup>89</sup>Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
Journal of Medicinal Chemistry|March 18, 2005
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)Paul A J Janssen, Paul J Lewi, Eddy Arnold, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Biorxiv : the Preprint Server for Biology|November 3, 2020
Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromesRajendra Karki, Bhesh Raj Sharma, Shraddha Tuladhar, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
Plos Pathogens|August 14, 2015
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionMartina Kovarova, Olivia D Council, Abhijit A Date, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 30, 2019
[<sup>18</sup>F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's diseaseSandra Sanabria Bohórquez, Jan Marik, Annie Ogasawara, et al.
Science (New York, N.Y.)|December 14, 2004
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisKoen Andries, Peter Verhasselt, Jerome Guillemont, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2020
Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosisLucia Macken, Stephen Bremner, Heather Gage, et al.
Oncotarget|March 31, 2016
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1Simon-Peter Williams, Annie Ogasawara, Jeff N Tinianow, et al.
British Journal of Clinical Pharmacology|November 13, 2021
A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitorJack A Brown, Joanne Bal, Monica Simeoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2022
Preclinical development of ZED8, an <sup>89</sup>Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
Journal of Medicinal Chemistry|March 18, 2005
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)Paul A J Janssen, Paul J Lewi, Eddy Arnold, et al.
Pageof 21